300412 证券代码：300412 证券简称：迦南科技 公告编号：2023-042 浙江迦南科技股份有限公司 第五届监事会第十四次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 1、会议通知时间与方式 （3）召开方式：以现场结合通讯方式召开 （4）主持人：监事会主席王虎根先生 （5）监事出席会议情况：应出席监事 3 人，实际出席监事 3 人 本次会议符合《公司法》和《公司章程》等有关规定，所作的决议合法有效。 二、监事会会议审议情况 1、审议通过《关于公司 2023 年半年度报告及其摘要的议案》 浙江迦南科技股份有限公司（以下简称"公司"）第五届监事会第十四次会 议通知于 2023 年 8 月 7 日以微信、电话及电子邮件等通讯方式送达全体监事 2、会议召开的时间、方式和表决情况 （1）会议时间：2023 年 8 月 17 日下午 （2）召开地点：公司三楼会议室 经审核，监事会认为董事会编制和审核公司 2023 年半年度报告的程序符合 法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反映了公司 的实际情况，不 ...

证券代码：300412 证券简称：迦南科技 公告编号：2023-041 300412 2、会议召开的时间、地点和方式 本次会议符合《公司法》和《公司章程》等有关规定，所作的决议合法有效 浙江迦南科技股份有限公司 第五届董事会第十四次会议决议公告 1、审议通过《关于公司 2023 年半年度报告及其摘要的议案》 1、会议通知时间与方式 浙江迦南科技股份有限公司（以下简称"公司"）第五届董事会第十四次会 议通知于 2023 年 8 月 7 日以微信、电话及电子邮件等通讯方式送达全体董事 二、董事会会议审议情况 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 （1）会议时间：2023 年 8 月 17 日下午 13:30 （2）召开地点：公司三楼会议室 （3）召开方式：以现场结合通讯方式召开 （4）董事出席会议情况：应出席董事 7 人，实际出席董事 7 人 （5）主持人：董事长方正先生 （6）列席人员：监事及高级管理人员 特此公告。 浙江迦南科技股份有限公司董事会 具体内容详见同日披露在巨潮资讯网的《公司 2023 年半年度报告》和《公 司 2 ...

的波动体现了投资者对公司发展战略和经营情况的信心和认可度，涉 及宏观经济、市场预期及资金供求等综合因素，未来公司将努力做好 各项经营工作，以带动二级市场股价走势，回报投资者对公司的信任， 也提醒广大投资者注意投资风险，感谢关注。 4、贵司的健康产业园项目，现在还有在推进吗 答：您好，目前健康产业园正在进行搬迁前的准备工作，公司将 全力以赴推进试生产和达产。感谢关注！ 5、请问贵公司有没有回购股份的计划 答：您好，公司暂无回购计划，未来如有相关计划公司会严格按 照相关法律法规及时履行信息披露义务。感谢您对公司的关注！ 证券代码：300412 证券简称：迦南科技 浙江迦南科技股份有限公司 投资者关系活动记录表 编号：20230510 投资者关系活动 类别 □特定对象调研 □分析师会议 □媒体采访 业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （请文字说明其他活动内容） 参与单位名称及 人员姓名 公司投资者 时间 2023 年 5 月 10 日 15:00～17:00 地点 同花顺路演平台 上市公司接待人 员姓名 1、董事长兼总裁 方正先生 2、董事会秘书兼副总裁 晁虎先生 3、财务总监 徐海智先生 4 ...

Financial Performance - The company's revenue for Q1 2023 was ¥199,699,286.27, a decrease of 4.98% compared to ¥210,175,206.49 in the same period last year[4] - Net profit attributable to shareholders was ¥8,219,096.97, down 54.58% from ¥18,094,190.28 year-on-year[4] - Basic and diluted earnings per share decreased by 66.67%, from ¥0.06 to ¥0.02[4] - Total operating revenue for Q1 2023 was CNY 199,699,286.27, a decrease of 4.5% compared to CNY 210,175,206.49 in Q1 2022[21] - Net profit attributable to the parent company was CNY 8,219,096.97, down 54.5% from CNY 18,094,190.28 in Q1 2022[23] - The company reported a net profit of CNY 6,162,715.32, a decline of 66.3% compared to CNY 18,279,869.43 in the same period last year[22] - Earnings per share (EPS) for Q1 2023 was CNY 0.02, down from CNY 0.06 in Q1 2022[23] Cash Flow - The net cash flow from operating activities improved by 52.95%, reaching -¥33,479,624.14, compared to -¥71,165,049.69 in the previous year[4] - The company’s cash flow from operating activities showed a positive trend, indicating improved liquidity management[25] - The net cash flow from operating activities was -33,479,624.14, an improvement from -71,165,049.69 in the previous year[26] - Total cash inflow from investment activities was 121,965,034.04, significantly higher than 20,170,367.01 in the same period last year[26] - The net cash flow from investment activities was 8,290,766.67, recovering from -205,152,264.61 in the previous year[26] - Cash inflow from financing activities totaled 48,567,554.75, compared to 3,488,013.11 in the previous year[26] - The net cash flow from financing activities was 2,883,399.30, an improvement from -5,218,450.43 in the previous year[26] - The total cash and cash equivalents at the end of the period were 202,116,081.26, compared to 186,311,065.29 at the end of the previous year[27] - The company received 120,000,000.00 in cash from investment recoveries, a significant increase from 20,000,000.00 in the previous year[26] - The company paid 40,000,000.00 in cash to repay debts, compared to 5,000,000.00 in the previous year[26] - The total cash outflow from operating activities was 284,527,598.76, slightly lower than 293,690,811.66 in the previous year[26] - The company reported a decrease in cash and cash equivalents by 22,487,606.00, compared to a decrease of 281,573,638.67 in the previous year[27] Assets and Liabilities - Total assets increased by 1.65% to ¥2,541,213,386.09 from ¥2,500,027,855.85 at the end of the previous year[4] - The company's total current assets amount to ¥1,837,095,986.57, an increase from ¥1,795,092,839.28 at the beginning of the year[19] - Inventory has increased to ¥870,925,206.74 from ¥766,468,161.33, reflecting a growth of approximately 13.6%[19] - The total liabilities increased to CNY 1,451,591,179.70 from CNY 1,416,568,364.78, reflecting a growth of 2.5%[22] - The company’s total liabilities include short-term borrowings of ¥143,142,680.56 and accounts payable of ¥363,516,580.64[19] - The total equity attributable to shareholders of the parent company was CNY 1,047,332,748.72, up from CNY 1,039,113,651.76[22] Expenses - Research and development expenses rose by 36.11%, amounting to an increase of ¥517.92 million, reflecting the company's commitment to new product and technology development[9] - Sales expenses increased by 31.38%, primarily due to the expansion of the sales team and related marketing costs[9] - Total operating costs increased to CNY 198,382,700.24, up 4.3% from CNY 190,384,320.25 in the previous year[22] - Research and development expenses rose to CNY 19,521,806.32, up 36.5% from CNY 14,342,570.02 in Q1 2022[22] Shareholder Information - The total number of common shareholders at the end of the reporting period is 33,005[12] - Canaan Technology Group Limited holds 16.68% of shares, making it the largest shareholder with 83,040,200 shares[12] - Canaan Technology Group Limited is the controlling shareholder, with significant family ties among the top shareholders[12] - The number of restricted shares held by executives remains at 24,585,891 after a slight reduction due to the release of 457,500 shares[15] Certification and Market Position - The company received high-tech enterprise certification for its subsidiary on January 31, 2023, enhancing its market position[16] Return on Equity - The weighted average return on equity decreased to 0.79% from 1.59% year-on-year[4]

浙江迦南科技股份有限公司 关于举行 2022 年度业绩说明会的公告 浙江迦南科技股份有限公司(以下简称"公司")2022 年度报告及其摘要 已于 2023 年 4 月 20 日披露于巨潮资讯网。为使广大投资者进一步了解公司 2022 年度经营情况，公司定于 2023 年 5 月 10 日（星期三）下午 15:00-17:00 在同花顺网上路演互动平台举办 2022 年度业绩说明会，本次年度业绩说明 会将采用网络远程的方式举行，投资者可登陆"同花顺网上路演互动平台" （https://board.10jqka.com.cn/ir）参与本次年度业绩说明会。 参加本次业绩说明会的人员包括：董事长兼总裁方正先生、董事会秘书 兼副总裁晁虎先生、财务总监徐海智先生、独立董事许小明女士及保荐代表 人吴义铭先生。为充分尊重投资者、提升交流的针对性，现就公司 2022 年 度业绩说明会提前向投资者公开征集问题，广泛听取投资者的意见和建议。 投 资 者 可 于 2023 年 5 月 10 日 （ 星 期 三 ） 15:00 前访问 https://board.10jqka.com.cn/rs/pc/detail?roadshow ...

Financial Performance - The company reported a significant loss for the year, primarily due to large impairment provisions and increased period expenses[5]. - The net profit attributable to shareholders was a loss of ¥75,201,420.17 in 2022, a decrease of 202.04% from a profit of ¥73,697,375.98 in 2021[21]. - The net profit after deducting non-recurring gains and losses was a loss of ¥85,398,061.37, a decline of 553.58% compared to a profit of ¥56,109,464.68 in 2021[21]. - The company reported a net cash flow from operating activities of ¥68,616,352.64, which is an 8.54% decrease from ¥75,025,262.77 in 2021[21]. - The company achieved total revenue of 1,103.43 million RMB in 2022, representing a year-on-year growth of 4.14%[68]. - The pharmaceutical equipment sector accounted for 84.82% of total revenue, with a year-on-year growth of 17.38%[75]. - The gross profit margin for the pharmaceutical equipment sector was 31.03%, a decrease of 4.31% compared to the previous year[77]. - The company reported a significant decline in revenue from the warehousing and logistics sector, which fell by 38.19% to ¥158,462,675.35[75]. Business Strategy and Development - The company plans to focus on its main business to enhance its industry position, business competitiveness, and sustainable development capabilities[5]. - The company aims to improve its operating performance through various measures described in the report[5]. - The company is positioned as a leader in the manufacturing of intelligent factory equipment for oral solid dosage forms, providing comprehensive solutions for pharmaceutical enterprises[33]. - The company is actively pursuing international market opportunities, capitalizing on the shift towards domestic substitution of imported pharmaceutical equipment[44]. - The company aims to enhance its overall solution capabilities, evolving from a pharmaceutical equipment supplier to a comprehensive service provider for pharmaceutical enterprises[46]. - The company is focusing on high-end pharmaceutical equipment and complex formulation production technologies as key development areas[43]. - The company is committed to continuous innovation and upgrading to maintain competitiveness in the evolving pharmaceutical equipment landscape[43]. Research and Development - The company has established a full product service research and development chain, including information consulting, pharmaceutical research, equipment support, and clinical trials, enhancing its overall service capabilities[59]. - The company has obtained a total of 911 national authorized patents, including 54 invention patents, reflecting its strong intellectual property management and innovation capabilities[62]. - The company completed key R&D projects, including high-closed wet granulation production and automated solid-state fermentation equipment, aimed at enhancing product safety and market competitiveness[86]. - Research and development (R&D) investment amounted to CNY 80.20 million in 2022, representing 7.27% of total revenue, up from 6.32% in 2021[89]. - The number of R&D personnel increased by 12.01% to 345 in 2022, with a notable rise in the proportion of personnel holding bachelor's degrees to 64.52%[89]. Market Trends and Industry Outlook - The global pharmaceutical market is expected to continue growing due to factors such as population increase, aging society, and rising health awareness, which will drive demand for pharmaceutical equipment[34]. - The global pharmaceutical market is expected to grow at a CAGR of 3%-6% to reach $1.6 trillion by 2025, with oncology drugs projected to exceed $260 billion by 2025, growing at a CAGR of 9%-12%[35]. - The pharmaceutical market in China is expected to maintain a stable growth trend post-public health events, with significant increases in original new drug usage driving this growth[35]. - The pharmaceutical manufacturing industry's total profit in 2022 was ¥4,288.7 billion, a decline of 31.8% year-on-year[39]. Corporate Governance and Compliance - The company has established independent financial and operational systems, ensuring that its assets and operations are distinct from those of its controlling shareholders[139]. - The company is committed to improving its corporate governance structure in accordance with relevant laws and regulations, protecting the rights of all shareholders[134]. - The company has conducted various investor communications, including performance briefings and industry discussions, to maintain transparency with stakeholders[130]. - The company has not faced any administrative penalties due to environmental issues during the reporting period[174]. - The company has ensured that all remuneration payments were made in full according to the established standards[149]. Employee Management and Development - The total number of employees at the end of the reporting period was 1,754, including 638 at the parent company and 1,116 at major subsidiaries[159]. - Employee training programs are prioritized, focusing on various aspects such as onboarding, skills training, and management development, with plans to enhance training efforts in 2023[162]. - The company emphasizes performance-based salary management, linking compensation to individual and team performance to attract and retain talent[161]. - The company has a structured remuneration decision process based on profitability and performance[149]. Financial Management and Fund Utilization - The company raised a total of RMB 270 million through the issuance of 35.57 million shares at an issue price of RMB 7.59 per share[106]. - The company has committed to investing RMB 180 million in the "Intelligent Equipment" project, with no funds utilized as of the reporting date[109]. - The company has not reported any issues or discrepancies in the use and disclosure of raised funds[111]. - The company has not engaged in any securities or derivative investments during the reporting period[102][103]. Risks and Challenges - The company faces uncertainty regarding its ability to continue as a going concern, as indicated by the negative net profits over the last three years[22]. - The company faces risks from policy changes in the pharmaceutical industry that could impact demand for its products, necessitating timely adjustments in business strategies[123]. - The company will expand its product series and extend its industrial chain to mitigate risks from intensified market competition in the pharmaceutical equipment sector[124]. - The company has acquired significant goodwill from past acquisitions, which is subject to impairment testing; if future performance does not meet expectations, it may negatively impact the company's profits[128].

证券代码：300412 证券简称：迦南科技 浙江迦南科技股份有限公司 投资者关系活动记录表 编号：20151214 | --- | --- | --- | |---------------------------|--------------------------|--------------------------------------------------------| | | | | | | ■ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活 | □ 新闻发布会 □路演活动 | | | 动类别 | □ 现场参观 | | | | □其他 | | | 调研单位 | | 国联证券股份有限公司（刘生平赴公司调研） | | 时间 | 2015 年 12 月 14 | 日（上午 10:00—11:00 ） | | | | 浙江省温州市永嘉县瓯北镇东瓯工业区园区大道迦南科技一楼 | | 地点 | 会议室 | | | 上市公司接待 | 副总经理兼董秘：陈永兴 | | | 人员姓名 | 董事办工作人员：晁虎 | | | 投资者关系活 动主要内容介 | | 一、公司作 ...

证券代码：300412 证券简称：迦南科技 浙江迦南科技股份有限公司 投资者关系活动记录表 编号：20161014 | --- | --- | --- | |-----------------|---------------------------------------------|--------------------------------------------------------| | | | | | | ■ | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 投资者关系活 | □ 新闻发布会 □路演活动 | | | 动类别 | □ 现场参观 | | | | □其他 | | | 调研单位 | | 海通证券股份有限公司研究员贺文斌、南方基金管理有限公司 | | | 研究员孙昊阳 | | | 时间 | 2016 年 10 月 14 | 日（下午 15:00—16:00 ） | | 地点 | 会议室 | 浙江省温州市永嘉县瓯北镇东瓯工业区园区大道迦南科技一楼 | | 上市公司接待 | 董事、总经理：方正 | | | 人员姓名 | 副总经理兼董秘：晁虎 董事办工作人员： ...